BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10190946)

  • 1. The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival.
    Cervantes F; Hernández-Boluda JC; Ferrer A; Cid J; Montserrat E
    Haematologica; 1999 Apr; 84(4):324-7. PubMed ID: 10190946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Philadelphia chromosome-positive chronic myeloid leukemia in the elderly: presenting features, natural history and survival].
    Hernández-Boluda JC; Cervantes F; Camós M; Costa D; Rafel M; Montserrat E
    Med Clin (Barc); 1999 May; 112(15):565-7. PubMed ID: 10365381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Features of chronic myeloid leukemia at diagnosis. Study of a series of 134 cases].
    Jonte F; Barez A; Soto I; Rayón C; Carrera D; Coma A; Pérez Llanderal J; Arribas M
    Sangre (Barc); 1992 Oct; 37(5):345-50. PubMed ID: 1293773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term survival in chronic myeloid leukemia: frequency and fundamental characteristics in a series of 100 patients].
    Cervantes F; Bosch F; Terol MJ; Pereira A; Rozman C
    Sangre (Barc); 1993 Apr; 38(2):93-6. PubMed ID: 8516734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
    Hasford J; Pfirrmann M; Shepherd P; Guilhot J; Hehlmann R; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Steegmann JL; Thaler J
    Haematologica; 2005 Mar; 90(3):335-40. PubMed ID: 15749665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation.
    J Clin Oncol; 1999 Jun; 17(6):1858-68. PubMed ID: 10561226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
    De Souza CA; Vigorito AC; Ruiz MA; Nucci M; Dulley FL; Funcke V; Tabak D; Azevedo AM; Byington R; Macedo MC; Saboya R; Penteado Aranha FJ; Oliveira GB; Zulli R; Martins Miranda EC; Azevedo WM; Lodi FM; Voltarelli JC; Simões BP; Colturato V; De Souza MP; Silla L; Bittencourt H; Piron-Ruiz L; Maiolino A; Gratwohl A; Pasquini R
    Haematologica; 2005 Feb; 90(2):232-7. PubMed ID: 15710577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
    Kantarjian H; O'Brien S; Cortes J; Giles F; Thomas D; Kornblau S; Shan J; Beth Rios M; Keating M; Freireich E; Talpaz M
    Cancer; 2003 Jul; 98(1):81-5. PubMed ID: 12833459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
    Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
    Giles FJ; Kantarjian HM; Cortes J; Thomas DA; Talpaz M; Manshouri T; Albitar M
    Cancer; 1999 Sep; 86(5):805-13. PubMed ID: 10463979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
    Soupir CP; Vergilio JA; Dal Cin P; Muzikansky A; Kantarjian H; Jones D; Hasserjian RP
    Am J Clin Pathol; 2007 Apr; 127(4):642-50. PubMed ID: 17369142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic features of Nigerians with chronic myeloid leukemia.
    Boma PO; Durosinmi MA; Adediran IA; Akinola NO; Salawu L
    Niger Postgrad Med J; 2006 Mar; 13(1):47-52. PubMed ID: 16633379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
    Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
    Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinico-pathologic features of chronic myeloid leukemia and risk stratification according to Sokal score.
    Syed NN; Usman M; Khaliq G; Adil SN; Khurshid M
    J Coll Physicians Surg Pak; 2006 May; 16(5):336-9. PubMed ID: 16756777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
    Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
    Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.